Satsuma Pharmaceuticals to Release Earnings on Friday
| STSADelisted Stock | USD 1.10 0.01 0.90% |
About 62% of Satsuma Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Satsuma Pharmaceuticals suggests that many traders are alarmed regarding Satsuma Pharmaceuticals' prospects. The current market sentiment, together with Satsuma Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Satsuma Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Satsuma |
Satsuma Pharmaceuticals is set to post its quarterly earnings results on Friday, March 17th. Satsuma Pharmaceuticals Trading Up 4.0 percent NASDAQ STSA traded up 0.04 on Thursday, hitting 0.91. 40,884 shares of the companys stock were exchanged, compared to its average volume of 142,725. The stock has a 50-day moving average
Read at thelincolnianonline.com
 |
Satsuma Pharmaceuticals Fundamental Analysis
We analyze Satsuma Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Satsuma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Satsuma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Satsuma Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Satsuma Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Satsuma Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Satsuma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Satsuma Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Satsuma Pharmaceuticals Related Equities
| CYCN | Cyclerion Therapeutics | 58.82 | ||||
| FBRX | Forte Biosciences | 18.65 | ||||
| TIL | Instil Bio | 16.79 | ||||
| ASMB | Assembly Biosciences | 10.72 | ||||
| KRON | Kronos Bio | 10.34 | ||||
| LRMR | Larimar Therapeutics | 7.44 | ||||
| PEPG | PepGen | 6.69 | ||||
| CTMX | CytomX Therapeutics | 6.25 | ||||
| ERAS | Erasca | 5.04 | ||||
| SNTI | Senti Biosciences | 1.42 | ||||
| ACHL | Achilles Therapeutics | 0.94 | ||||
| PMVP | Pmv Pharmaceuticals | 0.63 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| ADXN | Addex Therapeutics | 1.82 | ||||
| MNOV | MediciNova | 3.37 | ||||
| CING | Cingulate | 3.67 | ||||
| PHVS | Pharvaris | 7.49 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Satsuma Stock
If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |